As endothelial dysfunction in common in chronic kidney disease [19] and endothelial VAP-1 can participate in inflammation by binding granulocytes, lymphocytes and monocytes, with the aid of SSAO activity [1, 2], VAP-1 might be considered as a novel biomarker for cardiovascular diseases in kidney patients, in particular those with diabetes. This evidence concerns the gene AOC3 and endothelial dysfunction.